Within the next six months, Novo Nordisk will find out whether its drug semaglutide can be used as a treatment for obesity, aside from its use as a drug against diabetes in US patients.
The Danish pharmaceutical giant as used a priority review voucher, which cuts off many months from the estimated review time at the US Food and Drug Administration (FDA). Novo Nordisk bought the voucher from Australian biotech firm Medicines Development for Global Health for an unknown price last year.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Production Director 
Laboratory technician for process development and clinical manufacturing 
Industrial Designer- Design Engineer 
Senior Chemical Safety Advisor 
Project Manager & Scrum Master 
Senior Manager, Clinical Trial Budget 
Quality System Manager 
Key Account Manager, Europe and Asia 
Client Talent Acquisition Specialist 
Clinical Trial Manager for development of in vitro diagnostics 
Senior Project Manager (GMP - Life Science) 
Consultant Manager 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Account Manager 
Analytical Senior Scientist 
Director for innovative pre-clinical testing unit